Reports
Sale
Anti Tuberculosis Therapeutics Market Size, Trends, Report: By Treatment Type: First-Line of Drugs, Second-Line of Drugs, Others; By Disease Type: Active TB, Latent TB, Others; By Diagnosis: Blood Tests, Imaging Tests, Sputum Tests, Others; By Route of Administration; By Dosage Form; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Anti Tuberculosis Therapeutics Market Outlook
The anti tuberculosis therapeutics market size was valued at USD 1354 million in 2023, driven by the increasing incidence of tuberculosis and the rising number of studies around tuberculosis therapeutics. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 to achieve a value of USD 2589.8 million by 2032.
Anti Tuberculosis Therapeutics Market Overview
Tuberculosis (TB) is caused by mycobacterium tuberculosis. Tuberculosis treatment involves a combination of antibiotics which are recommended by the healthcare professionals to the patients. These antibiotics are taken over several months to ensure the complete removal of the bacteria and prevent the development of drug-resistant strains of the disease. The standard regimen for tuberculosis treatment often includes multiple drugs to target different aspects of the infection and prevent the bacteria from becoming resistant to treatment. Some key medications used in anti-tuberculosis therapy include Isoniazid (INH), Rifampin (RIF), Pyrazinamide (PZA), ethambutol, streptomycin and other aminoglycosides, fluoroquinolones.
The anti tuberculosis therapeutics market growth is expected to grow significantly during the forecast period owing to several pivotal factors including the escalating prevalence of tuberculosis worldwide, with a stressful rise in multi-drug resistant (MDR) and extensively drug-resistant (XDR) cases in developing nations. This surge in incidences is fostering increased demand for anti-tuberculosis medications in the forecast period, propelling the market growth. Furthermore, the market growth is driven by the proactive measures by government and private organizations to spread awareness about tuberculosis.
Research and Development to Aid the Market Growth
The market is expected to witness significant growth in the forecast period, driven by key developments and ongoing research initiatives. For instance, the SimpliciTB trial's evaluation of the BPaMZ regimen has recently exhibited promising efficacy and treatment-shortening potential, elevating optimism and hope for effective tuberculosis management among patients and their families. Such trials are expected to drive the anti tuberculosis therapeutics market growth in the forecast period.
Isoniazid as a Potential Treatment for Alzheimer's Disease
Furthermore, the market growth is anticipated to be driven by the exploration of Isoniazid as a potential treatment for Alzheimer's disease presents a dual opportunity, that includes expanded therapeutic applications beyond TB treatment. Such observational research may lead to more experiments and observational studies in the market to explore the full potential of other drugs in the treatment of TB, resulting in widespread application opportunities, and bolstering the market growth.
Rising Efforts by Researchers to Drive the Growth
Additionally, a recent modeling study discussing the introduction of a new TB vaccine in low or middle-income countries (LMICs), concluded that it will promise substantial health and economic benefits to the anti tuberculosis therapeutics market in the countries. These modeling studies by researchers may pull the traction of pharmaceutical and biotechnology companies to understand the urgency of the situation and create opportunities for them to fill a crucial gap in the market, likely to contribute to the anti tuberculosis therapeutics market share during the forecast period.
Clinical Trials to Drive Significant Development
In November 2023, TB Alliance launched a new Pan-Phase 2 clinical trial incorporating elements of Phase 2a, b, and c, identified as NC-009, to evaluate the safety and efficacy of a combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, components of TB Alliance’s BPaL regimen. This regimen has the potential to shorten and improve treatment for both drug-sensitive and drug-resistant tuberculosis (TB), one of the world’s deadliest infectious diseases. Results from preclinical and Phase 1 studies presented at the Union Conference showed that the new compound when compared with bedaquiline (a TB medicine in the same drug class), eliminated TB bacteria faster and had a potentially safer profile.
Such clinical trials are expected to drive the anti tuberculosis therapeutics market growth by enabling healthcare professionals to pay attention to the formulation of the TB drugs that they are prescribing to TB patients. However, this approach is also expected to provide convenience as exhibited by the results, with chances of non-compliance while improving success rates of the treatment, boosting the market growth.
Anti Tuberculosis Therapeutics Market Segmentations
Market Breakup by Treatment Type
- First-Line of Drugs
- Second-Line of Drugs
- Others
Market Breakup by Disease Type
- Active TB
- Latent TB
- Others
Market Breakup by Diagnosis
- Blood Tests
- Imaging Tests
- Sputum Tests
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Dosage Form
- Tablets
- Capsules
- Injections
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Others
Market Breakup by -7MM
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Anti Tuberculosis Therapeutics Market Regional Analysis
The United States has been leading the market and is likely to continue leading the market in the forecast period as well. For instance, in September 2023, the United States, through USAID, announced more than USD 23 million, as well as new efforts to support countries in fighting tuberculosis (TB) and reaching global targets set at a meeting during United Nations High Level Week. Working with Congress, the new efforts that are part of USAID’s Global Accelerator to End TB Plus package are part of more than USD 394 million in planned FY 2023 investments and illustrate USAID's steadfast commitment to ending TB globally. Such funding activities play a crucial role in incentivizing research and deelopment in pharmaceutical companies to develop innovative therapies, drugs, and treatment modalities for TB. Such funding may also support manufacturing and the widespread distribution of drugs to fulfill a crucial gap of unmet medical needs in this domain, likely to aid the anti tuberculosis therapeutics market size in the forecast period.
Geographically, the Middle East and African regions are expected to lead the market growth in the forecast period. The presence of a huge patient pool and the unavailability of effective treatments are expected to provide opportunities for pharmaceutical companies and other organizations to fill a crucial gap in the market. The incidence is also expected to increase in countries that are developing with small incomes.
Anti Tuberculosis Therapeutics Market: Competitor Landscape
In September 2023, Global health aid agency Unitaid wrote to Johnson & Johnson's (JNJ.N) CEO, Joaquin Duato, urging "immediate action" to expand access to the company's tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives. While J&J has lowered the price of bedaquiline, which is used to treat drug-resistant tuberculosis (DR-TB), Unitaid said it was an "incomplete solution" and countries like South Africa, Belarus, and Ukraine were not benefiting.
The key features of the anti tuberculosis therapeutics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AstraZeneca
- Johnson & Johnson Private Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Novartis
- Allergan
- Merck & Co.
- STI Pharma
- Endo International plc
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
Please note that this only represents a partial' list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Disease Type |
|
| Breakup by Diagnosis |
|
| Breakup by Route of Administration |
|
| Breakup by Dosage Form |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Tuberculosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Tuberculosis Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Tuberculosis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Tuberculosis Epidemiology Forecast (2017-2032)
5.3.1 Germany Tuberculosis Epidemiology Forecast (2017-2032)
5.3.2 France Tuberculosis Epidemiology Forecast (2017-2032)
5.3.3 Italy Tuberculosis Epidemiology Forecast (2017-2032)
5.3.4 Spain Tuberculosis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Tuberculosis Epidemiology Forecast (2017-2032)
5.4 Japan Tuberculosis Epidemiology Forecast (2017-2032)
6 Anti Tuberculosis Therapeutics Market Overview – Seven Major Markets
6.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
6.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
7 Anti Tuberculosis Therapeutics Market Landscape – Seven Major Markets
7.1 Anti Tuberculosis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Anti Tuberculosis Therapeutics Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Anti Tuberculosis Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Anti Tuberculosis Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Anti Tuberculosis Therapeutics Market Segmentation – Seven Major Markets
11.1 Anti Tuberculosis Therapeutics Market by Treatment Type
11.1.1 Market Overview
11.1.2 First-Line of Drugs
11.1.3 Second-Line of Drugs
11.1.4 Others
11.2 Anti Tuberculosis Therapeutics Market by Disease Type
11.2.1 Market Overview
11.2.2 Active TB
11.2.3 Latent TB
11.2.4 Others
11.3 Anti Tuberculosis Therapeutics Market by Diagnosis
11.3.1 Market Overview
11.3.2 Blood Tests
11.3.3 Imaging Tests
11.3.4 Sputum Tests
11.3.5 Others
11.4 Anti Tuberculosis Therapeutics Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Others
11.5 Anti Tuberculosis Therapeutics Market by Dosage Form
11.5.1 Market Overview
11.5.2 Tablets
11.5.3 Capsules
11.5.4 Injections
11.5.5 Others
11.6 Anti Tuberculosis Therapeutics Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Speciality Clinics
11.6.4 Others
11.7 Anti Tuberculosis Therapeutics Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Anti Tuberculosis Therapeutics Market
12.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
12.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
12.3 Anti Tuberculosis Therapeutics Market by Disease Type
12.4 Anti Tuberculosis Therapeutics Market by Treatment Type
13 EU-4 and United Kingdom Anti Tuberculosis Therapeutics Market
13.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
13.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
13.3 Germany Anti Tuberculosis Therapeutics Market Overview
13.3.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.3.2 Anti Tuberculosis Therapeutics Market by Treatment Type
13.4 France Anti Tuberculosis Therapeutics Market Overview
13.4.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.4.2 Anti Tuberculosis Therapeutics Market by Treatment Type
13.5 Italy Anti Tuberculosis Therapeutics Market Overview
13.5.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.5.2 Anti Tuberculosis Therapeutics Market by Treatment Type
13.6 Spain Anti Tuberculosis Therapeutics Market Overview
13.6.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.6.2 Anti Tuberculosis Therapeutics Market by Treatment Type
13.7 United Kingdom Anti Tuberculosis Therapeutics Market Overview
13.7.1 Anti Tuberculosis Therapeutics Market by Disease Type
13.7.2 Anti Tuberculosis Therapeutics Market by Treatment Type
14 Japan Anti Tuberculosis Therapeutics Market
14.1 Anti Tuberculosis Therapeutics Market Historical Value (2017-2023)
14.2 Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
14.3 Anti Tuberculosis Therapeutics Market by Disease Type
14.4 Anti Tuberculosis Therapeutics Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 AstraZeneca
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Johnson & Johnson Private Limited
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Eli Lilly and Company
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Mylan N.V.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Teva Pharmaceutical Industries Ltd.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Sanofi
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Novartis
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Allergan
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Merck & Co.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 STI Pharma
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Endo International plc
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Fresenius Kabi AG
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Hikma Pharmaceuticals PLC
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
22 Anti Tuberculosis Therapeutics Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1354 million in 2023 driven by the rising incidence of tuberculosis.
The market is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 and is likely to reach a market value of USD 2589.8 million by 2032.
The rising prevalence of tuberculosis, increased demand for better therapeutics, initiatives by government and private organizations to spread awareness, research activities, and collaboration between key players are some of the major factors driving the market growth.
Rising investments to support countries in fighting tuberculosis is a major trend influencing market growth.
The 7 major regions of the market include the United States, EU-4, the United Kingdom, and Japan.
Treatment types for tuberculosis include first-line of drugs and second line of drugs, among others.
Types of tuberculosis include active TB and latent TB, among others.
It can be diagnosed with the help of blood tests, imaging tests, and sputum tests, among others.
Oral and parenteral are the different routes of administration in the market.
End users in the market include hospitals and specialty clinics, among others.
Key players in the market include AstraZeneca, Johnson & Johnson Private Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis, Allergan, Merck & Co., STI Pharma, Endo International plc, Fresenius Kabi AG, and Hikma Pharmaceuticals PLC.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER